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intraocular pressure (IOP)-lowering efﬁcacy in patients with
open-angle glaucoma. The purpose of this study was to carry out
a cost-effectiveness analysis of latanoprost versus timolol,
bimatoprost and travoprost in the treatment of glaucoma in
Spain. METHODS: A cost-effectiveness analysis was performed
by building a decision analytical model. Effectiveness data (treat-
ment success was deﬁned as patient with successful IOP control:
£18mmHg) were obtained from published clinical trials mea-
suring IOP-lowering of drugs under evaluation. Health care
resource utilization was taken from the aforementioned clinical
trials and a local expert panel. Only direct medical costs were
included in the model (drug acquisition, diagnostic procedures,
ophthalmologist visits and treatment of therapeutic failures).
Drug acquisition cost data were obtained from ofﬁcial sources
while the rest of the data were taken from a national health care
costs database. The perspective selected for this analysis was the
National Health Service and the time horizon chosen was for 6
months, the time that patients were included in most of the clin-
ical trials found. RESULTS: Cost per patient associated with the
use of timolol, latanoprost, bimatoprost and travoprost was
368€, 379.5€, 377€, and 383€, respectively while their cost/effec-
tiveness ratio was 1116, 702, 785, and 912€ per each patient
with a treatment success. The incremental cost-effectiveness ratio
of using latanoprost compared to timolol, bimatoprost and
travoprost was 54, 40, and -32€ per each additional patient
achieving optimal IOP control. CONCLUSIONS: The results of
this pharmacoeconomic model demonstrates that latanoprost is
a more cost-effective option than the rest of evaluated alterna-
tives. Therefore, latanoprost should be considered as the thera-
peutic option to be selected routinely in the treatment of
open-angle glaucoma in Spain.
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OBJECTIVES: To estimate the cost effectiveness of ﬁrst-line
latanoprost treatment for POAG compared with beta-blockers,
travoprost or bimatoprost using a previously developed eco-
nomic model. METHODS: A decision analytical model was
developed where POAG patients either receive latanoprost, beta-
blockers, travoprost or bimatoprost as ﬁrst-line therapy. Subse-
quent therapy switches were determined by average time that
patients persisted with each therapy. Persistency data was
obtained from a retrospective cohort study (Reardon, 2004). IOP
controlled days are estimated from this by assuming that switch-
ing therapy implies failure to control IOP for half the time on
therapy. Resource use was obtained from UK expert opinion and
included ophthalmologist consultations, drug usage and glau-
coma surgery. The NHS perspective was taken and included
direct costs only (NHS 2002 reference costs inﬂated to 2003
prices using HCHS inﬂation index, PSSRU 2003, MIMS 2004).
A one-year time horizon was used to capture all relevant resource
use and to assess main clinical outcomes. RESULTS: The model
estimates that for a cohort of 1000 patients, ﬁrst-line treatment
with latanoprost results in 10,397, 14,341, and 17,142 more
days of IOP control than patients treated initially with a beta-
blocker, travoprost or bimatoprost respectively. Compared with
beta-blockers, ﬁrst-line latanoprost therapy reduces management
and surgical costs. Overall treatment costs are higher for travo-
prost (£29,597 more) and bimatoprost (£36,650 more) com-
pared with ﬁrst-line latanoprost therapy due to higher rates 
of subsequent therapy and surgery. CONCLUSIONS: Overall,
compared to other prostaglandins and beta-blockers, latanoprost
ﬁrst-line therapy results in greater beneﬁt to patients in terms of
more days of IOP control. Latanoprost ﬁrst-line therapy com-
pared with travoprost and bimatoprost results in greater persis-
tency and lower costs.
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OBJECTIVES: Latanoprost/timolol is one of the ﬁxed-combina-
tion more used in daily medical practice to treat glaucoma. The
aim of this analysis is to carry out a pharmacoeconomic evalu-
ation of two ﬁxed-combinations: latanoprost/timolol (L-T) com-
pared to dorzolamide/timolol (D-T) as second line treatment 
in patients with glaucoma in Spain. METHODS: A cost-
effectiveness analysis was performed by building a decision ana-
lytic model. Effectiveness data (patient with an IOP reduction at
least of >25%) were obtained from a multicenter-randomized
trial showing that the L-T combination had signiﬁcantly better
efﬁcacy in reducing IOP than D-T combination[1]. Health care
resource utilisation was taken from the aforementioned clinical
trial and a local expert panel. Only direct medical costs were
included in the model. Drug acquisition costs were obtained
from ofﬁcial sources, while the rest of data were taken from a
national health care-cost database. The perspective selected for
this analysis was the National Health Service and the time
horizon chosen was for 3 months, the time that patients were
followed up in the referenced clinical trial. RESULTS: The per-
centage of patients with a good control of IOP was higher 
with L-T combination (80 vs 65%, p < 0.01) and the cost/
effectiveness ratio was lower with L-T combination than with D-
T combination: 719 vs 840€ per each patient with a treatment
success. The incremental cost-effectiveness ratio of using L-T
combination compared to D-T combination was 196€ per each
additional patient achieving optimal IOP control. CONCLU-
SIONS: This model demonstrates that L-T combination is a more
efﬁcient therapeutic option than D-T combination. Therefore, L-
T combination should be considered as the second line therapy
to be selected routinely when IOP cannot be reduced appropri-
ately with only a drug in Spain. [1] Shin DH, Feldman RM, Sheu
W-P. Ophthalmology 2004;111:276–82.
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OBJECTIVES: To estimate resource utilization and costs of end-
stage glaucoma patients receiving low vision care (LVC) via a
multi-center retrospective cohort design. METHODS: A random
sample of 61 open-angle glaucoma charts from 2 US LVC 
facilities with ophthalmologic follow-up was retrospectively
reviewed. Patients with a diagnosis of primary open-angle glau-
coma were followed for at least two years within the time
window from 1998–2003. Clinical and economic data were
abstracted beginning with initial low vision visit. Clinical data
collected included: patient demographics, baseline medical and
